Transfer of T Cell Specificity for the Treatment of Breast Cancer: A Preclinical Study PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Transfer of T Cell Specificity for the Treatment of Breast Cancer: A Preclinical Study PDF full book. Access full book title Transfer of T Cell Specificity for the Treatment of Breast Cancer: A Preclinical Study by . Download full books in PDF and EPUB format.
Author:
Publisher:
ISBN:
Category :
Languages : en
Pages : 0
Get Book Here
Book Description
Overexpression of Her-2/neu is one of the major alterations in breast cancer and is associated with metastatic disease, poor prognosis and overall survival. Her-2/neu is a self antigen, therefore, self-tolerance is a major burden for the induction of effective antitumor immune responses. Clinical trials show that immunizations with neu-antigens do not promote a potent protective mediated immune response. In order to develop a therapy to target Her-2/neu expressing tumors, we have devised a strategy where we can endow T cells with antitumor specificity and bypass the effect of self-tolerance. We developed an approach by genetic engineering where we have genetically altered T cell populations to express high affinity T cell receptors (TCR) chains specific for Her-2/neu. High affinity TCR were obtained from A2.1 transgenic mice immunized with A2. 1 -Her-2/neu immunodominant epitopes. The TCR genes from the CTLs were cloned and engineered to be expressed on T cells. T cells expressing these engineered TCR can recognize and kill Her-2/neu expressing breast tumors. These results demonstrate a novel strategy to target Her-2/neu positive tumors for the treatment of breast cancer.
Author:
Publisher:
ISBN:
Category :
Languages : en
Pages : 0
Get Book Here
Book Description
Overexpression of Her-2/neu is one of the major alterations in breast cancer and is associated with metastatic disease, poor prognosis and overall survival. Her-2/neu is a self antigen, therefore, self-tolerance is a major burden for the induction of effective antitumor immune responses. Clinical trials show that immunizations with neu-antigens do not promote a potent protective mediated immune response. In order to develop a therapy to target Her-2/neu expressing tumors, we have devised a strategy where we can endow T cells with antitumor specificity and bypass the effect of self-tolerance. We developed an approach by genetic engineering where we have genetically altered T cell populations to express high affinity T cell receptors (TCR) chains specific for Her-2/neu. High affinity TCR were obtained from A2.1 transgenic mice immunized with A2. 1 -Her-2/neu immunodominant epitopes. The TCR genes from the CTLs were cloned and engineered to be expressed on T cells. T cells expressing these engineered TCR can recognize and kill Her-2/neu expressing breast tumors. These results demonstrate a novel strategy to target Her-2/neu positive tumors for the treatment of breast cancer.
Author: Niels Schaft
Publisher:
ISBN:
Category :
Languages : en
Pages : 164
Get Book Here
Book Description
Author:
Publisher:
ISBN:
Category :
Languages : en
Pages : 95
Get Book Here
Book Description
This project is focused on the development of novel tumor vaccines directed at MUC1 and other tumor antigens. Our specific aims are: 1) To assess the effectiveness of vaccine formulations against MUC1 and other tumor antigens in the prevention and treatment of spontaneous breast carcinomas in mice and 2) To translate the most effective vaccine strategies into phase I clinical trials in patients with high and low tumor burden. The model of spontaneous mammary cancer is the MUCl-expressing polyoma middle T antigen mice (MMT). We have tested four vaccines in the preclinical mouse model: 1) liposomal MUCl tandem repeat peptide, 2) dendritic cells (DCs) pulsed with tumor lysate, 3) DCs fused to MMT tumor cells, and 4) adoptive transfer of MUCl-specific cytotoxic T lymphocytes (CTLs). All vaccines elicited a strong immunological response, although CTLs in the tumor environment were tolerized. DCs pulsed with lysate accompanied by co-stimulation (4-lBB) greatly reduced tumor burden and reduced tolerance in MMT mice. Aim 2, to develop a clinical trial, is underway. The clinical trial protocol is under review. It is a phase I trial testing MUCl and HER-2/neu class I and class II peptides in breast cancer patients free of disease.
Author: Suzanne L. Walker
Publisher:
ISBN: 9781635930184
Category :
Languages : en
Pages :
Get Book Here
Book Description
Author: Manmeet Ahluwalia
Publisher: Springer Nature
ISBN: 3030234177
Category : Medical
Languages : en
Pages : 421
Get Book Here
Book Description
This book provides a comprehensive overview of brain metastases, from the molecular biology aspects to therapeutic management and perspectives. Due to the increasing incidence of these tumors and the urgent need to effectively control brain metastatic diseases in these patients, new therapeutic strategies have emerged in recent years. The volume discusses all these innovative approaches combined with new surgical techniques (fluorescence, functional mapping, integrated navigation), novel radiation therapy techniques (stereotactic radiosurgery) and new systemic treatment approaches such as targeted- and immunotherapy. These combination strategies represent a new therapeutic model in brain metastatic patients in which each medical practitioner (neurosurgeon, neurologist, medical oncologist, radiation oncologist) plays a pivotal role in defining the optimal treatment in a multidisciplinary approach. Written by recognized experts in the field, this book is a valuable tool for neurosurgeons, neuro-oncologists, neuroradiologists, medical oncologists, radiation oncologists, cognitive therapists, basic scientists and students working in the area of brain tumors.
Author: Changjun Yin
Publisher: Frontiers Media SA
ISBN: 2889451801
Category :
Languages : en
Pages : 237
Get Book Here
Book Description
The immune system employs TLOs to elicit highly localized and forceful responses to unresolvable peripheral tissue inflammation. Current data indicate that TLOs are protective but they may also lead to collateral tissue injury and serve as nesting places to generate autoreactive lymphocytes. A better comprehension of these powerhouses of disease immunity will likely facilitate development to unprecedented and specific therapies to fight chronic inflammatory diseases.
Author: Christian Münz
Publisher: Springer
ISBN: 331922834X
Category : Medical
Languages : en
Pages : 493
Get Book Here
Book Description
Epstein Barr virus (EBV) was discovered as the first human tumor virus around 50 years ago. Since its discovery in Burkitt’s lymphoma it has been associated with various other malignancies, infectious mononucleosis and even autoimmune diseases. The two book volumes on EBV summarize the first 50 years of research on this tumor virus, starting with historical perspectives on discovery, oncogenicity and immune control, reviewing the role that the virus plays in the various associated diseases and concluding with a discussion on how the immune system keeps persistent EBV infection under control in healthy EBV carriers and can be used to treat EBV associated diseases. The respective 32 chapters are written by international experts from three continents for health care providers, biomedical researchers and patients that are affected by EBV. The assembled knowledge should help to understand EBV associated diseases better and to develop EBV specific vaccination in the near future.
Author: Magdalena Klink
Publisher: Springer Nature
ISBN: 3030913112
Category : Medical
Languages : en
Pages : 358
Get Book Here
Book Description
Now, it its second edition, this book summarizes the role of immune cells in tumor suppression and progression. It describes in detail why tumor cells can survive and spread in spite of the antitumor response of immune cells. Since immunotherapy is an attractive approach to cancer therapy, this book also provides information on the two main strategies: monoclonal antibodies and adaptive T cell immunotherapy, with a focus on recent human clinical trials. A newly added chapter also focuses on the role of Natural Killer cells in tumor progression. The book provides a state-of-the-art, comprehensive overview of immune cells in cancer and is an indispensable resource for researchers and practitioners working or lecturing in the field of cancer research and immunology.
Author: Sara Hurvitz
Publisher: Elsevier Health Sciences
ISBN: 0323581234
Category : Medical
Languages : en
Pages : 264
Get Book Here
Book Description
Get a quick, expert overview of clinically-focused topics and guidelines that are relevant to testing for HER2, which contributes to approximately 25% of breast cancers today. This concise resource by Drs. Sara Hurvitz, and Kelly McCann consolidates today’s available information on this growing topic into one convenient resource, making it an ideal, easy-to-digest reference for practicing and trainee oncologists.
Author: Linda M. Liau
Publisher: Springer Science & Business Media
ISBN: 1592590357
Category : Medical
Languages : en
Pages : 369
Get Book Here
Book Description
An authoritative panel of researchers and clinicians critically reviews the entire field to provide a comprehensive guide to modern brain tumor immunotherapy and thereby enhance future research in this area. The contributors detail many of the key laboratory experiments and clinical protocols that are currently being investigated, integrate the available information from previous and ongoing research, and help define the current status of the field. Topics range from adoptive cellular and antibody-mediated immunotherapy of brain tumors to tumor vaccines and related strategies, and include many vanguard experimental strategies and immunological techniques for studying brain tumor immunotherapy. Cutting-edge and comprehensive, Brain Tumor Immunotherapy brings together all the important recent advances in our understanding of central nervous system tumor immunology and illustrates in powerful detail the many new applications now harnessing the immune response for brain tumor therapeutics.
